Pieris Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Note 7 - Accrued Expenses 1 (Tables)

Note 7 - Accrued Expenses 1 (Tables) - Pieris Pharmaceuticals, Inc. [Member]

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

		*September 30,*				*December 31,*
		*2024*				*2023*
Compensation expense		$	2,306			$	6,448
Research and development fees			—				968
Accrued accounts payable			60				558
Other current liabilities			1,031				363
Accrued license obligations			56				213
Total		$	3,453			$	8,550

		Years Ended December 31,
		2023				2022
Compensation expense		$	6,448			$	3,015
Research and development fees			968				5,758
Accrued accounts payable			558				1,245
Other current liabilities			363				483
Accrued license obligations			213				245
Total		$	8,550			$	10,746

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

		*Severance and Benefits Costs*
Balance at June 30, 2024		$	2,850
Adjustments to restructuring charges		$	183
Cash payments			(805	)
Balance at September 30, 2024		$	2,228

		*Severance and Benefits Costs*
Balance at December 31, 2023		$	5,105
Adjustments to restructuring charges		$	(86	)
Cash payments			(2,791	)
Balance at September 30, 2024		$	2,228

		Severance and Benefits Costs
Restructuring expenses		$	7,523
Cash payments		$	(2,418	)
Balance at December 31, 2023		$	5,105